Business Context and Reporting Period
Company: Cree, Inc. (Note: The filing metadata references "WOLFSPEED, INC.", but the document text identifies the registrant as "CREE, INC.", the predecessor to Wolfspeed).
Reporting Period: Quarterly report (Form 10-Q) for the period ended March 25, 2001.
Business Overview: Cree is a leader in developing semiconductors made from silicon carbide (SiC) and gallium nitride (GaN), primarily manufacturing Light Emitting Diodes (LEDs) and SiC wafers. The company operates two segments: Cree (LEDs, wafers, government contracts) and UltraRF (acquired December 2000, RF power semiconductors).
Key Financial Metrics
| Metric | Three Months Ended March 25, 2001 | Nine Months Ended March 25, 2001 | Three Months Ended March 26, 2000 | Nine Months Ended March 26, 2000 |
|---|---|---|---|---|
| Total Revenue | $53.4 million | $132.5 million | $29.5 million | $75.2 million |
| Gross Profit | $25.7 million | $68.3 million | $15.8 million | $38.0 million |
| Gross Margin | 48% | 52% | 54% | 51% |
| Net Income (Loss) | $(5.2) million | $21.3 million | $9.0 million | $19.2 million |
| Diluted EPS | $(0.07) | $0.28 | $0.12 | $0.28 |
| Operating Cash Flow (9mo) | $57.5 million (vs. $26.0 million prior year) | |||
| Cash & Equivalents | $117.1 million (as of March 25, 2001) | |||
| Working Capital | $215.2 million (as of March 25, 2001) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 81% year-over-year for the quarter and 76% for the nine-month period. This was driven by a 127% increase in LED chip volume and the acquisition of UltraRF.
- Acquisition Impact: The December 2000 acquisition of UltraRF contributed $9.3 million in revenue for the quarter. However, it also resulted in a one-time non-cash charge of $17.4 million for in-process research and development (IPR&D) costs, which caused the quarterly net loss.
- Margin Compression: Gross margin decreased to 48% from 54% year-over-year. This was due to the lower-margin UltraRF business (42% margin) and contractual price declines on LED products (average sales prices down 27% year-over-year).
- Expense Increases: R&D expenses rose 64% and SG&A expenses rose 76% year-over-year, largely due to UltraRF integration and significant legal costs related to patent litigation.
- Capital Expenditures: Investing activities used $23.5 million in cash for the nine-month period, including $88.2 million in property and equipment purchases to expand manufacturing capacity.
Guidance, Outlook, and Risks
- Product Outlook: Management expects ultra-bright LED products to continue replacing older high-brightness devices. A new "megabright" chip is targeted for volume production in June 2001. Average LED sales prices are expected to decline 25-30% for the full fiscal year.
- Cost Reduction: The company is prioritizing cost reduction through vendor negotiations and process improvements to offset declining product prices and maintain profitability.
- Legal Risks: Significant ongoing patent litigation with Nichia Corporation in the U.S. and Japan. Nichia has asserted counterclaims alleging infringement and trade secret misappropriation. The outcome is uncertain and could materially impact operations.
- Customer Concentration: UltraRF revenue is heavily concentrated with Spectrian Corporation, though the company is working to diversify its customer base.
- Stock Repurchase: The Board authorized a repurchase program for up to 7 million shares. As of March 25, 2001, 1.85 million shares had been repurchased for $30.7 million.
Investor Verification Checklist
- Acquisition Accounting: Verify the treatment of the $17.4 million IPR&D charge and the $81.7 million goodwill from the UltraRF acquisition.
- Legal Proceedings: Monitor the status of the patent infringement lawsuit against Nichia Corporation, including the pending motions for summary judgment and counterclaims.
- Product Mix Transition: Confirm the ramp-up rates and yield improvements for the new ultra-bright and megabright LED products to ensure they offset price declines.
- Customer Diversification: Assess progress in reducing reliance on Spectrian for UltraRF revenue.
- Capital Allocation: Review the balance between capital expenditures for capacity expansion and the stock repurchase program.